Fig. 4

CD8⁺ T-cells, CD8⁺ DCs and granulocytes are necessary for in vivo efficacy of hAB21 monotherapy. a MC38 colon carcinoma cells were implanted subcutaneously in C57BL/6 mice. Two days post-implant, mice were treated with anti-CSF1R, anti-GR1 or anti-CD8 depleting antibodies. Mice with established tumors were randomized, n = 5 mice/group, and treated intraperitoneally with PBS or hAB21. Mice were treated three times every 3 days. Depleting antibodies were dosed on days 2, 5, 10 and 15 post-implantation. Unpaired two-tailed t-test between PBS and hAB21 were determined for days indicated. *p < 0.05, **p < 0.01, ***p < 0.001. b MC38 cells were implanted subcutaneously in wild type and Baft3-deficient C57BL/6 mice. Eight days post mice were randomized, n = 5 mice/group, and dosed intratumorally with vehicle or AB21. Mice were treated four times, every 3 days